文献速递肿瘤 PET/CT放射性药物与辐射防护

[¹⁸F]F-AraG PET显像检测T细胞激活:细胞特异性免疫示踪剂的功能补充

Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.
PubMed 文献 · EJNMMI Res · 2026-04-19

本综述总结了[¹⁸F]F-AraG PET显像用于免疫监测的临床前与临床证据,阐述其分子机制、免疫细胞特异性及早期治疗反应检测性能。该示踪剂通过活化T细胞线粒体核苷酸补救途径聚集,可区分活跃与惰性免疫细胞浸润,早期临床数据显示治疗开始后数天内即可捕捉治疗反应。

要点

  • [¹⁸F]F-AraG通过dGK活性升高和SAMHD1表达降低在活化T细胞中聚集,反映免疫激活功能状态。
  • 与抗CD8靶向示踪剂相比,[¹⁸F]F-AraG可区分活跃与惰性免疫细胞浸润。
  • 早期临床数据显示[¹⁸F]F-AraG PET可在治疗开始后数天内捕捉治疗反应。

核心结论

  • 互补的PET策略可通过评估T细胞激活、细胞毒性参与和空间浸润实现无创功能免疫监测,推进个性化免疫引导治疗。
  • 实现该潜力需要前瞻性临床验证、统一的定量标准以及持续开发短半衰期放射性核素标记的构建体。

研究设计与样本

  • 本综述汇总[¹⁸F]F-AraG PET显像作为免疫监测工具的当前临床前和临床证据,检查其分子机制、免疫细胞特异性和检测早期治疗反应的性能。

主要发现

  • [¹⁸F]F-AraG在活化T细胞中因dGK活性升高和SAMHD1表达降低而聚集,作为免疫激活的功能成像生物标志物。
  • 与抗CD8靶向放射性示踪剂相比,[¹⁸F]F-AraG通过区分活跃与惰性免疫细胞浸润提供独特优势。
  • 早期临床数据表明[¹⁸F]F-AraG PET图像可在治疗开始后数天内捕捉治疗反应。

临床怎么用

  • [¹⁸F]F-AraG PET可用于无创功能免疫监测,评估T细胞激活、细胞毒性参与和空间浸润。
  • 该显像有望支持治疗分层、适应性治疗指导及与其他成像模态联合应用。

局限性

  • 实现临床整合潜力需要前瞻性临床验证和统一的定量标准。
  • 需要持续开发针对空间分辨率、患者调度和辐射负担优化的短半衰期放射性核素标记构建体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Solid tumors remain a clinical challenge due to the complexity of the tumor microenvironment (TME) and high variability of immune responses to treatment. Monitoring immunological activity within the TME has emerged as a critical determinant of tumor progression and therapeutic outcome. With the advent of radiotracers that can non-invasively visualize immunological activity, research interest has grown in their potential to enhance precision oncology and support adaptive clinical decision-making. Among these, metabolic positron emission tomography (PET) imaging with [¹⁸F]F-AraG, a fluorine-18-labeled guanine nucleoside analog, offers a promising functional approach for visualizing activated T-cells by leveraging their unique mitochondrial nucleotide salvage pathways. Unlike antibody-based immuno-PET tracers that typically bind to cell surface biomarkers, [¹⁸F]F-AraG accumulates in activated T-cells due to elevated deoxyguanosine kinase (dGK) activity and reduced SAMHD1 expression, serving as a functional imaging biomarker of immune activation. MAIN BODY: This review summarizes current preclinical and clinical evidence on [¹⁸F]F-AraG PET imaging as a tool for immune monitoring, examining its molecular mechanism, immune cell specificity, and performance in detecting early treatment responses. Compared with anti-CD8-targeted radiotracers, [¹⁸F]F-AraG offers distinct advantages by distinguishing active from inert immune cell infiltration. Early clinical data demonstrate that [¹⁸F]F-AraG PET images can capture treatment response within days of treatment initiation. Furthermore, the review discusses future directions for clinical integration, including its potential in treatment stratification, adaptive therapy guidance, and combination with other imaging modalities. CONCLUSION: These complementary PET strategies enable non-invasive functional immune monitoring by assessing T cell activation, cytotoxic engagement, and spatial infiltration, thereby advancing personalized, immune-guided treatment. Realizing this potential requires prospective clinical validation, harmonized quantitative standards, and continued development of short-lived radionuclide-labeled constructs optimized for spatial resolution, patient scheduling, and radiation burden.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Almutairi WM, Gopaulchan M, Bhaskara R, et al. Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers. EJNMMI Res. 2026. PMID: 42001384. doi:10.1186/s13550-026-01436-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。